EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World outcomes of intravitreal treatment switching in retinal diseases: Analysis of 3,038 treated cases

Tugce Horozoglu Ceran iD, Gullu Jabbarova, Rabia Yokus, Muberra Akdogan iD, Mustafa Dogan iD

European Journal of Ophthalmology · 2026

DOI: 10.1177/11206721261471209 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Ophthalmology, 2026. Verfasst von Tugce Horozoglu Ceran und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Faculty of Medicine, Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkiye. Hauptthemen laut MEDLINE: Visual Acuity, Angiogenesis Inhibitors, Dexamethasone, Glucocorticoids. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate the frequency and patterns of intravitreal therapy (IVT) switching in retinal diseases and describe associated visual acuity outcomes in real-world clinical practice. Materials and Methods This retrospective, monocentric study evaluated consecutive IVT-treated cases at a tertiary retina unit. Demographic data, diagnoses, initial agent, injection number, and treatment switches were recorded. Best-corrected visual acuity (BCVA, LogMAR) was assessed at baseline and final follow-up. Switching was defined as a change to another anti-VEGF agent or intravitreal dexamethasone (DEX) implant for inadequate functional and/or anatomical response. BCVA changes were compared using appropriate tests, stratified by indication (diabetic macular edema [DME], neovascular age-related macular degeneration [nAMD], retinal vein occlusion [RVO]).

Results

A total of 3,038 IVT-treated cases (11,345 injections) were analyzed. The main indications were DME (55.5%), nAMD (36.4%), and RVO (6.0%). Overall, 22.9% of treated cases underwent treatment switching, most frequently in DME (24.8%) and nAMD (20.8%). Within-group analyses showed significant BCVA improvement after switching in DME (p = 0.001), RVO (p = 0.032), and nAMD (p = 0.009), while non-switched groups showed no significant change. Aflibercept was the most commonly selected second-line agent (81.7%), and the aflibercept subgroup showed significant within-group BCVA improvement ( p < 0.001). Because treatment choice was not randomized, this finding should not be interpreted as evidence of superiority over other second-line agents.

Conclusions

In this retrospective real-world cohort, treatment switching was common in routine retinal practice, and switched cases showed within-group BCVA improvement in some diagnostic subgroups. These findings should be interpreted as descriptive associations rather than evidence of a causal treatment effect.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Visual AcuityAngiogenesis InhibitorsDexamethasoneGlucocorticoidsDrug SubstitutionRetinal DiseasesHumansRetrospective StudiesIntravitreal InjectionsFemaleVascular Endothelial Growth Factor AMaleAgedTreatment OutcomeReceptors, Vascular Endothelial Growth FactorRanibizumabRecombinant Fusion ProteinsMiddle AgedAged, 80 and overTomography, Optical CoherenceFollow-Up Studies

Stichwörter der Autor:innen

Afliberceptanti-VEGFdiabetic macular edemaintravitreal injectionneovascular age-related macular degenerationtreatment switching

Substanzen

Angiogenesis InhibitorsDexamethasoneGlucocorticoidsVascular Endothelial Growth Factor AReceptors, Vascular Endothelial Growth FactorRanibizumabRecombinant Fusion ProteinsVEGFA protein, humanaflibercept

Autor:innen und Institutionen

  • Department of Ophthalmology, Faculty of Medicine, Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkiye.
  • Department of Ophthalmology, Ministry of Health Rize State Hospital, Rize, Turkiye.

ORCID-Profile: Tugce Horozoglu Ceran, Muberra Akdogan, Mustafa Dogan

Zitieren

APA

Horozoglu Ceran, T., Jabbarova, G., Yokus, R., Akdogan, M., & Dogan, M. (2026). Real-World outcomes of intravitreal treatment switching in retinal diseases: Analysis of 3,038 treated cases. European Journal of Ophthalmology. https://doi.org/10.1177/11206721261471209

Vancouver

Horozoglu Ceran T, Jabbarova G, Yokus R, Akdogan M, Dogan M. Real-World outcomes of intravitreal treatment switching in retinal diseases: Analysis of 3,038 treated cases. European Journal of Ophthalmology. 2026. doi:10.1177/11206721261471209

BibTeX
@article{HorozogluCeran2026,
  author = {Horozoglu Ceran, Tugce and Jabbarova, Gullu and Yokus, Rabia and Akdogan, Muberra and Dogan, Mustafa},
  title = {Real-World outcomes of intravitreal treatment switching in retinal diseases: Analysis of 3,038 treated cases},
  journal = {European Journal of Ophthalmology},
  year = {2026},
  doi = {10.1177/11206721261471209}
}
Kostenlos starten →